Accueil > Actualité
Actualite financiere : Actualite bourse

Merck: approval for triple-negative breast cancer drug

( - Merck announced on Tuesday that the European Commission has approved its blockbuster immunotherapy Keytruda for the treatment of so-called "triple negative" breast cancer.

The US biopharmaceutical company said that Brussels has based its decision on the results of a Phase 3 clinical trial that showed the antibody, combined with chemotherapy, reduced the risk of death by 37% compared to chemotherapy alone.

The Commission's green light is for the post-operative treatment of adult patients with early or advanced triple-negative breast cancer, a type of cancer with a high risk of recurrence.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.